On a relative basis, the stock has outperformed the S&P 500 by 4.56% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.35% in the last 1 week, and is up 9.13% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 6.25% and the 50-Day Moving Average is 5.96%.
Amgen (NASDAQ:AMGN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $163.45 and $161.56 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $164.57. The buying momentum continued till the end and the stock did not give up its gains. It closed at $163.28, notching a gain of 0.33% for the day. The total traded volume was 3,179,693 . The stock had closed at $162.74 on the previous day.
The company Insiders own 0.2% of Amgen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -25.24% . Institutional Investors own 83.25% of Amgen shares. During last six month period, the net percent change held by insiders has seen a change of -25.24%. In a related news,The officer (EVP, Operations) of Amgen Inc, Balachandran Madhavan sold 30,000 shares at $154.12 on May 4, 2016. The Insider selling transaction had a total value worth of $4,623,600. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.